Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enterotoxigenic Escherichia coli vaccine + cholera vaccine
- Development stage
- Unknown
- Lead developer
- Valneva
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
The enterotoxigenic *Escherichia coli* (ETEC) vaccine + cholera vaccine is an oral, killed whole-cell vaccine candidate designed to provide dual protection against ETEC-mediated diarrhea and cholera. The formulation consists of formalin-inactivated *E. coli* bacteria that over-express key colonization factor antigens (CFAs), including CFA/I, CS1, CS2, and CS3, which are essential for the bacteria to adhere to the intestinal mucosa. This bacterial component is combined with the recombinant B subunit of the cholera toxin (rCTB). The rCTB serves a dual purpose: it induces immunity against *Vibrio cholerae* and provides cross-protection against the ETEC heat-labile toxin (LT) due to the high degree of structural and antigenic homology between the two toxins. By inducing local intestinal IgA responses, the vaccine aims to prevent both bacterial colonization and toxin-induced secretory diarrhea.
- Other names
- Oral inactivated ETEC vaccineETEC-cholera vaccineInactivated ETEC plus rCTB vaccine
02
Targets
GM1 (GM1 ganglioside)CTBS (Cholera toxin B subunit)SLAMF7 (Signaling lymphocytic activation molecule family member 7)CS5 (Colonization factor antigen 5)CS3 (Coli surface antigen 3)CFA/I (Colonization factor antigen I)
Beyond the preview
Go deeper on enterotoxigenic Escherichia coli vaccine + cholera vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enterotoxigenic Escherichia coli vaccine + cholera vaccine.